Financial News Search | Sharemaestro Newsreel

21:40 23 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Insmed (INSM) insider William Lewis plans 10,700-share stock sale

Insmed Inc. (INSM) insider William Lewis has filed to sell 10,700 shares of common stock through Merrill Lynch, categorized as Stock Plan Activity, with the transaction dated July 23, 2026. The filing also details prior sales made by Lewis over the past three months, …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

12:10 23 Jul 2026

Stocktwits Earnings Main company 🇲🇽 Mexico

TMDX: Transmedics Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides current stock information for Transmedics Group Inc (TMDX), including its latest stock price, market capitalization, volume, and key financial metrics. It also features recent news headlines related to TransMedics, such as upcoming earnings reports and expansion activities. Additionally, the page includes …

TMDX main company TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%

11:40 23 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Insmed's second-quarter business update will be webcast Aug. 6

Insmed (NASDAQ: INSM) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. The company will host a conference call for investors at 8:00 a.m. ET to discuss the results and provide a business update, with live access available via …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

11:10 23 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Militia Capital Management LLC Acquires New Shares in TransMedics Group, Inc. $TMDX

Militia Capital Management LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 16,600 shares valued at approximately $1.65 million during the first quarter. While the company's Q1 earnings missed expectations, revenue increased by 21.2% year-over-year. Analysts currently hold a consensus "Hold" …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

11:09 23 Jul 2026

MarketBeat Analyst action Main company 🇺🇸 United States

NewEdge Wealth LLC Purchases 41,504 Shares of Allison Transmission Holdings, Inc. $ALSN

NewEdge Wealth LLC increased its stake in Allison Transmission Holdings, Inc. by 7.4% during the first quarter, acquiring an additional 41,504 shares and bringing its total holding to 601,636 shares valued at approximately $70.4 million. The company reported strong Q1 earnings, with EPS of …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

09:10 23 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

TransMedics Group (TMDX) Projected to Post Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) is expected to announce its Q2 2026 earnings on Thursday, July 30th, with analysts projecting earnings of $0.50 per share and revenue of $183.7870 million. The company's stock has a consensus "Hold" rating and a consensus target price of $134.50 from …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

09:09 23 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

First Trust Advisors LP Buys 932,201 Shares of Allison Transmission Holdings, Inc. $ALSN

First Trust Advisors LP significantly increased its stake in Allison Transmission Holdings, Inc. (ALSN) by 85.2%, acquiring an additional 932,201 shares, bringing its total holdings to over 2 million shares valued at $237.2 million. Despite this large investment, Wall Street maintains a cautious "Hold" …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

18:26 22 Jul 2026

Bloomberg Law News Regulatory and legal Main company 🇺🇸 United States

TransMedics Investors Partially Advance Organ Delivery Lawsuit

A federal judge ruled that TransMedics Group Inc. must face allegations from investors who claim its CEO, Waleed Hassanein, knowingly or recklessly defrauded them through unsustainable forced-bundling practices in its organ transplant "Amazon Prime model." The court found a plausible inference of conscious intent …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

18:11 22 Jul 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake

JPMorgan Chase & Co. has reported a beneficial ownership of 10,365,622 shares of Insmed Incorporated common stock, constituting a 4.7% stake in the company. The filing specifies varying levels of sole and shared voting power, as well as dispositive power, maintained through several JPMorgan …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

14:40 22 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

German Armed Forces to Receive About 3,000 Armored EAGLE V Vehicles

Allison Transmission will supply its 2500 Specialty Series fully automatic transmissions for approximately 3,000 EAGLE V armored vehicles for the German Armed Forces, with deliveries beginning in 2027. This order, which includes an option for up to 2,000 additional vehicles, extends a 20-year partnership …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

14:10 22 Jul 2026

TradingView Market update Main company 🇺🇸 United States

TMDX5812024 Bond Profile — Key Metrics

This article provides a bond profile for TransMedics Group, Inc.'s TMDX5812024 bond. Key metrics such as the issue date, maturity date, outstanding amount, face value, and coupon rate are detailed. TransMedics Group, Inc. is described as a commercial stage medical technology company focused on …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

10:40 22 Jul 2026

Moomoo Analyst action Main company 🇺🇸 United States

Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207

Guggenheim has maintained its Buy rating for Insmed (INSM.US) and reiterated a target price of $207. This indicates a continued positive outlook from the firm regarding Insmed's stock performance.

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

09:40 22 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Hsbc Holdings PLC Purchases 71,229 Shares of Allison Transmission Holdings, Inc. $ALSN

HSBC Holdings PLC significantly increased its stake in Allison Transmission Holdings, Inc. by 46.7% in the first quarter of 2026, acquiring an additional 71,229 shares and bringing its total holding to 223,911 shares valued at approximately $25.9 million. This increase occurred despite cautionary analyst …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

09:11 22 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Insmed (INSM) Stock Could Be Pricey As Its 4.4x Run Continues

Insmed's stock has seen a significant 4.4x return over the past three years, but current valuation metrics suggest it might be overpriced. Despite positive 12-month data for treprostinil palmitil inhalation powder and progression to a Phase 3 trial, Insmed's price-to-sales (P/S) ratio of 28.7x …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

07:40 22 Jul 2026

MarketBeat Analyst action Main company 🇺🇸 United States

TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of "Hold" by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has received an average "Hold" rating from brokerages, with a consensus 1-year price target of $134.50. The company recently missed earnings estimates, reporting $0.30 EPS against an estimated $0.62, while revenue was in line with expectations. Shares were trading at …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

01:39 22 Jul 2026

scanx.trade Earnings Main company 🇺🇸 United States

TransMedics to report Q2 2026 financial results on August 4

TransMedics Group, Inc. will release its Q2 2026 financial results after market close on Tuesday, August 4, 2026. The medical technology company, which specializes in organ transplant therapy, will host a conference call at 4:30 p.m. ET to discuss its performance. Investors can access …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

20:54 21 Jul 2026

Stock Traders Daily Market update Main company 🇺🇸 United States

(TMDX) Movement as an Input in Quant Signal Sets

Transmedics Group Inc. (NASDAQ: TMDX) is exhibiting a mid-channel oscillation pattern with weak near-term and long-term sentiment, despite mid-term strength. Quantitative AI models have identified an exceptional 90.8:1 risk-reward short setup, targeting a 26.4% downside with minimal risk. Three distinct trading strategies—Position Trading, Momentum …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

20:39 21 Jul 2026

Stock Titan Earnings Main company 🇲🇽 Mexico

TransMedics will webcast its second-quarter results call Aug. 4

TransMedics (Nasdaq: TMDX) announced it will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results with investors. Prior earnings-date …

TMDX main company TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%

12:09 21 Jul 2026

GuruFocus Analyst action Main company 🇺🇸 United States

INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192

BMO Capital has initiated coverage on Insmed (INSM) with an Outperform rating and a price target of $192.00, effective July 21, 2026. GuruFocus assesses INSM as 40.5% undervalued with a GF Value™ of $179.86 but cautions investors due to its classification as a "Possible …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

11:09 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

INSM5182680 Bond Profile — Key Metrics

This article provides key metrics for the INSM5182680 bond issued by Insmed Incorporated. It details the bond's coupon rate, maturity date, issue date, and face value, along with a brief description of Insmed as a global biopharmaceutical company focusing on rare diseases.

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

04:39 21 Jul 2026

Brattleboro Reformer Earnings Main company 🇺🇸 United States

Allison Schedules Second Quarter 2026 Earnings Conference Call

Allison Transmission Holdings Inc. announced its second quarter 2026 financial results conference call will take place on Monday, August 3, 2026, at 5:00 p.m. EDT. Executives will discuss the company's financial performance, with the news release issued post-market on the same day. A live …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

01:41 21 Jul 2026

www.dicardiology.com Market update Main company 🇺🇸 United States

Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension

Insmed Inc. announced positive 12-month data from its open-label extension (OLE) study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The study demonstrated sustained improvements across all secondary efficacy measures, including six-minute walk distance, NT-proBNP concentration, and WHO Functional Class, with …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

22:41 20 Jul 2026

Investing.com Analyst action Main company 🇺🇸 United States

BMO initiates Insmed stock with outperform rating on respiratory franchise potential

BMO Capital has initiated coverage on Insmed Inc. (NASDAQ:INSM) with an outperform rating and a $192 price target, citing the strong potential of its respiratory franchise, particularly Brinsupri and Arikayce. The firm projects significant peak sales for Brinsupri and highlights additional multi-billion-dollar pipeline optionality …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

21:10 20 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Allison to release Q2 results after market close Aug. 3

Allison Transmission (NYSE: ALSN) is scheduled to hold its second-quarter 2026 earnings conference call on Monday, August 3, 2026, at 5:00 p.m. EDT. The company will release its financial results after market close on the same day. Investors can access the call via phone …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

16:39 20 Jul 2026

Cantech Letter Analyst action Main company 🇺🇸 United States

Buy Insmed for a double, this analyst says

Roth Capital Partners analyst Adam Walsh reiterated his "Buy" rating and $212.00 target on Insmed after the company released positive 12-month data from its TPIP extension study. The data showed durable improvement in six-minute walk distance for patients with pulmonary arterial hypertension, exceeding expectations …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

12:39 20 Jul 2026

Investing.com Analyst action Main company 🇺🇸 United States

Insmed stock price target maintained at $220 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $220 price target for Insmed (NASDAQ:INSM) following positive 12-month open-label extension data for its TPIP drug, indicating consistent efficacy and no new tolerability concerns. While this data de-risks the investment, the firm emphasizes that Phase …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

03:11 20 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?

Insmed (INSM) shares are in focus following positive 12-month data from an open-label extension study for treprostinil palmitil inhalation powder in pulmonary arterial hypertension. Despite recent share price volatility, analysts suggest Insmed is significantly undervalued, with a fair value of $197.14 against a current …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

09:11 19 Jul 2026

Webull Earnings Main company 🇺🇸 United States

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

Insmed has reported positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension, showing sustained improvements in clinical endpoints with no new safety signals. These results pave the way for a Phase 3 randomized, controlled trial, providing a new data point for investors …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

11:09 18 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Geneos Wealth Management Inc. Makes New Investment in TransMedics Group, Inc. $TMDX

Geneos Wealth Management Inc. has initiated a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the first quarter, acquiring 30,635 shares valued at approximately $3.05 million. This investment comes amidst mixed analyst sentiment, with the stock holding a consensus "Hold" rating despite missing Q1 …

TMDX main company

Sharemaestro market context Price below Trend Line 52 weeks -26.1%

18:40 17 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Allison Transmission (NYSE:ALSN) Given New $130.00 Price Target at Morgan Stanley

Morgan Stanley has raised its price target for Allison Transmission (NYSE:ALSN) to $130.00 from $126.00, maintaining an "equal weight" rating, suggesting a potential upside of 13.87%. This update comes after Allison Transmission reported strong quarterly results, with EPS of $2.57 and revenue of $1.41 …

ALSN main company

Sharemaestro market context Trend signal started 52 weeks +42.1%

16:39 17 Jul 2026

Moomoo Guidance Main company 🇺🇸 United States

A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237

This article provides an overview of recent analyst ratings for Insmed (INSM.US), highlighting a consensus price target range of $161 to $237. It outlines the bullish sentiment surrounding the stock based on these expert evaluations. The information suggests a positive outlook for Insmed's potential …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

13:10 17 Jul 2026

BioSpace Regulatory and legal Main company 🇺🇸 United States

Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

Insmed's investigational pulmonary arterial hypertension (PAH) drug, treprostinil palmitil inhalation powder (TPIP), demonstrated "impressive" long-term efficacy and biomarker improvements in an open-label extension study. Guggenheim Partners projects peak TPIP sales to exceed $6 billion across various indications, citing functional improvements and significant reductions in …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

13:10 17 Jul 2026

Investing.com Analyst action Main company 🇺🇸 United States

Insmed stock price target maintained at $200 by Stifel on trial data

Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and reinforces the drug's …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

09:11 17 Jul 2026

Moomoo Market update Main company 🇺🇸 United States

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional capacity, and clinical outcomes. Insmed is …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

21:27 16 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)

Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are presented in a slideshow …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

20:10 16 Jul 2026

Insmed Incorporated Investor Relations Earnings Main company 🇺🇸 United States

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP was well-tolerated with no new safety signals. …

INSM main company

Sharemaestro market context Price below Trend Line 52 weeks -6.2%

260 matching headlines